CAMBRIDGE -
The DJSI World Index recognizes the top 10 percent of companies in the S&P Global Broad Market Index for performance on environmental, social and governance (ESG) issues, which
Of the 318 companies named to DJSI World Index, Biogen led the biotechnology industry with the top scores in areas such as strategies to improve access to medicine and cost burden, innovation management, talent attraction, climate performance and reporting. In 2013 Biogen was the first
'At Biogen, we believe that responsible corporate leadership is a defining part of our culture and our ongoing business success. We are proud to top the DJSI World Index for the fifth time, an achievement that reflects Biogen's longstanding commitment to making advances in climate, health, equity and other urgent issues of our time while pioneering neuroscience,' said
The DJSI World Index ranking results from Biogen's outstanding performance on multiple dimensions of corporate responsibility, including an ongoing focus on health equity and access; ethical marketing practices and human capital development with a focus on diversity, equity and inclusion. It also reflects Biogen's emphasis on transparency and expanded public reporting on emerging risks, employee benefits and philanthropic contributions, among other issues.
'We congratulate Biogen for being included in the DJSI World Index. A DJSI distinction is a reflection of being a sustainability leader in your industry,' said
To bolster its ESG commitments, Biogen recently launched Healthy Climate, Healthy LivesTM, a 20-year initiative to eliminate fossil fuels across its operations and collaborate with renowned institutions to advance human health. The program includes research into the potential link between dementia and air pollution.
About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by
Biogen Safe Harbor
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about our strategy and plans and our ability to achieve our ESG goals, commitments and targets. These statements may be identified by words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would' and other words and terms of similar meaning. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation the risks of unexpected hurdles, costs or delays; uncertainty of success in the execution of our strategy and plans; the direct and indirect impact of the ongoing COVID-19 pandemic on our business, results of operations and financial condition and the risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the
Contact:
Tel: 1 617 679 4945
Email: public.affairs@biogen.com
(C) 2020 Electronic News Publishing, source